Antithrombin III binding protein
Leech-derived inhibitor that potentiates host antithrombin III activity — synergistic anticoagulation.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Leech-derived inhibitor that potentiates host antithrombin III activity — synergistic anticoagulation.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
This leech-derived factor's reported potentiation of antithrombin III does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only and rests largely on Russian-language literature.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 58,000 Da
- Source species
- Hirudo medicinalis
Biological Targets
- → antithrombin III complex
Key Citations
- Baskova IP, Nikonov GI (1985), Biokhimiia
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.